REGN Regeneron Pharmaceuticals
Excellent capital allocator, but patent-cliff biology makes durability harder to underwrite than the price implies.
The business
Regeneron discovers and manufactures biologic drugs, earning the bulk of profit from Eylea (anti-VEGF eye injections) plus a Sanofi profit-share on Dupixent (immunology) and a broader immuno-oncology/genetics pipeline (Libtayo, Regeneron Genetics Center-driven discovery).
Quality gate · 85/100
Moat & management
| Moat | narrow moat |
| Source | intangible |
| Trajectory | eroding |
| Management | excellent |
Patents and regulatory approvals create real but time-limited exclusivity; Eylea now faces biosimilar erosion (Eylea HD partially offsets) and Dupixent economics are shared and could face competition, so the moat depends on a productive R&D engine restocking the pipeline rather than a durable structural advantage.
Founder-led (Schleifer) with a strong capital allocation record — heavy reinvestment in R&D, disciplined M&A, buybacks that have shrunk share count (-1.2% CAGR), minimal leverage, no dilution.
Owner-earnings inputs
| Owner earnings (TTM) | 3.79B |
| Owner-earnings yield | 5.5% |
| Free-cash-flow yield | 5.5% |
| Growth used (normalized) | 5.0% |
| Market-implied growth (reverse DCF) | 3.9% |
| Terminal growth | 3.0% |
| Discount rate (hurdle) | 9.0% |
Projected owner earnings
| Yr | Owner earnings | Growth | PV |
|---|---|---|---|
| 1 | 3.96B | 5.0% | 3.64B |
| 2 | 4.16B | 4.9% | 3.50B |
| 3 | 4.35B | 4.7% | 3.36B |
| 4 | 4.55B | 4.6% | 3.22B |
| 5 | 4.75B | 4.4% | 3.09B |
| 6 | 4.96B | 4.3% | 2.95B |
| 7 | 5.16B | 4.1% | 2.82B |
| 8 | 5.37B | 4.0% | 2.69B |
| 9 | 5.57B | 3.9% | 2.57B |
| 10 | 5.78B | 3.7% | 2.44B |
| 11 | 5.99B | 3.6% | 2.32B |
| 12 | 6.19B | 3.4% | 2.20B |
| 13 | 6.40B | 3.3% | 2.09B |
| 14 | 6.60B | 3.1% | 1.97B |
| 15 | 6.80B | 3.0% | 1.87B |
Key risks
- Eylea/Eylea HD biosimilar and competitive erosion outpacing pipeline replacement
- Single-product concentration risk (Eylea+Dupixent are the large majority of profit)
- Binary clinical trial and regulatory outcomes for pipeline assets
- Drug pricing/IRA policy pressure on biologics economics
Catalysts
- Pipeline readouts in obesity, oncology, and genetic medicine diversifying revenue
- Continued Dupixent volume growth in new indications
- Eylea HD switch mitigating biosimilar loss
- Undervaluation narrative if pipeline delivers, per recent headlines
Recent news
score · 8 articles
- The Scientist With 1,000 Patents Fueling a Drug Powerhouse
- Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
- Here's What to Expect From Regeneron Pharmaceuticals’ Next Earnings Report
- Regeneron Pharmaceuticals (REGN) Rebounds As Undervalued View Holds, Is The Upside Already Priced In?
- The weight-loss drugs boom is creating both winners and wipeouts: One Big Investment Idea
- Merck Snags A First-Of-Its-Kind Approval, And Shares Jump
- Merck Stock Rises After U.S. Approval for Powerful Cholesterol-Cutting Pill
- Collect 9.8% On VRTX Stock Now, And Still Keep 15% Of Upside
⚠ maintenance capex ≈ min(capex, D&A), capped at FCF · Net cash 0.4B credited to value (interest stripped from owner earnings to avoid double-counting). · Price pays for ~4%/yr owner-earnings growth over 15y (reverse DCF); model credits 5%.